Compound Global Advisors, LLC Reduces Boston Scientific Position in Latest 13F Filing

Compound Global Advisors, LLC Reduces Boston Scientific Position in Latest 13F Filing

In its latest SEC 13F filing, Compound Global Advisors, LLC disclosed a notable reduction in its position in Boston Scientific (NYSE: BSX), a leading player in the Medical Biology industry. The hedge fund sold 46,160 shares of the company, maintaining its overall allocation to the stock at 1.46% of its portfolio. Despite the sell-off, the market value of the remaining holdings in Boston Scientific stands at an impressive $32.28 million.

Deep Dive into the Trade

According to the filing, Compound Global Advisors, LLC’s decision to sell shares of Boston Scientific did not alter its overall percentage allocation to the stock within its portfolio, which remains steady at 1.46%. The hedge fund currently owns approximately 0.02% of Boston Scientific's total outstanding shares. This move reflects a strategic adjustment rather than a complete exit from the position.

Boston Scientific operates in the Medical Biology sector, a space known for its innovation in medical devices and technologies. The company has been a consistent performer, making it a staple in many institutional portfolios.

Market Context: Why Did Compound Global Advisors Adjust Its Position?

Investors might wonder why Compound Global Advisors, LLC decided to trim its position in Boston Scientific. While the exact reasoning behind the sell-off is not disclosed, it could be attributed to portfolio rebalancing, profit-taking, or a strategic shift in focus. With Boston Scientific's strong market presence and Compound Global Advisors retaining a significant holding, this adjustment might be more about optimizing portfolio performance than a lack of confidence in the stock.

How Much of Boston Scientific Does Compound Global Advisors Own?

Post-trade, Compound Global Advisors, LLC holds a $32.28 million stake in Boston Scientific, representing 0.02% of the company's total outstanding shares. This positions the firm as a minor but notable stakeholder in the medical device giant.

Portfolio Impact

Boston Scientific now accounts for 1.46% of Compound Global Advisors, LLC's portfolio. This move reflects a marginal shift in the fund's overall exposure, suggesting that the firm remains committed to the stock while fine-tuning its portfolio allocation.

For a deeper dive into Compound Global Advisors, LLC’s full portfolio and historical 13F data, view their real-time holdings here.